Table 4.
Clinicopathological Features of EBVaGC and EBVnGC Grouped According to the Combining Expression PD-L1 and STING
| Characteristics | EBVaGC | EBVnGC | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STING & PD-L1+ (n=40) |
STING or PD-L1+ (n=17) |
STING & PD-L1– (n=19) |
p-value† | p-value‡ | p-value§ | STING & PD-L1+ (n=21) |
STING or PD-L1+ (n=97) |
STING & PD-L1– (n=92) |
p-value† | p-value‡ | p-value§ | ||
| Age, yr | |||||||||||||
| Mean±SD | 60.0±9.9 | 60.3±11.4 | 61.4±12.1 | 0.929 | 0.652 | 0.786 | 61.0±9.5 | 62.3±12.0 | 62.1±9.8 | 0.653 | 0.651 | 0.906 | |
| <60 | 15 (37.5) | 7 (41.2) | 7 (36.8) | 0.794 | 0.961 | 0.790 | 8 (38.1) | 34 (35.1) | 36 (39.1) | 0.792 | 0.930 | 0.562 | |
| ≥60 | 25 (62.5) | 10 (58.8) | 12 (63.2) | 13 (61.9) | 63 (64.9) | 56 (60.9) | |||||||
| Gender | |||||||||||||
| Male | 35 (87.5) | 15 (88.2) | 16 (84.2) | 0.716 | 0.951 | 0.893 | 17 (80.9) | 67 (69.1) | 65 (70.7) | 0.409 | 0.494 | 0.813 | |
| Female | 5 (12.5) | 2 (11.8) | 3 (15.8) | 4 (19.1) | 30 (30.9) | 27 (29.3) | |||||||
| Location | |||||||||||||
| Proximal | 29 (72.5) | 15 (88.2) | 15 (78.9) | 0.342 | 0.833 | 0.765 | 16 (76.2) | 60 (61.9) | 58 (63.1) | 0.214 | 0.253 | 0.866 | |
| Distal | 11 (27.5) | 2 (11.8) | 4 (21.1) | 5 (23.8) | 37 (38.1) | 34 (36.9) | |||||||
| Tumor size, cm | |||||||||||||
| Mean±SD | 5.1±2.6 | 4.3±2.3 | 4.1±2.5 | 0.251 | 0.142 | 0.786 | 5.1±2.1 | 4.9±2.4 | 4.6±2.4 | 0.790 | 0.467 | 0.448 | |
| <5 | 22 (55.0) | 12 (70.6) | 11 (57.8) | 0.272 | 0.834 | 0.429 | 10 (47.6) | 51 (52.6) | 55 (59.8) | 0.680 | 0.309 | 0.318 | |
| ≥5 | 18 (45.0) | 5 (29.4) | 8 (42.2) | 11 (52.4) | 46 (47.4) | 37 (40.2) | |||||||
| Differentiation | |||||||||||||
| Well/Moderate | 12 (30.0) | 6 (35.3) | 4 (26.3) | 0.694 | 0.683 | 0.562 | 6 (28.6) | 60 (61.9) | 47 (51.1) | 0.005* | 0.062 | 0.135 | |
| Poor | 28 (70.0) | 11 (64.7) | 15 (73.7) | 15 (71.4) | 37 (38.1) | 45 (48.9) | |||||||
| Histologic subtype | |||||||||||||
| LELC/CLR | 33 (82.5) | 12 (70.6) | 12 (63.2) | 0.313 | 0.103 | 0.637 | NA | NA | NA | ||||
| CA | 7 (17.5) | 5 (29.4) | 7 (36.8) | ||||||||||
| Lauren’s type | |||||||||||||
| Intestinal | 24 (60.0) | 8 (47.1) | 5 (26.3) | 0.368 | 0.016* | 0.196 | 5 (23.8) | 58 (59.8) | 60 (65.2) | 0.006* | <0.001* | 0.442 | |
| Diffuse/mixed | 16 (40.0) | 9 (52.9) | 14 (73.7) | 16 (76.2) | 39 (40.2) | 32 (34.8) | |||||||
| LVI | |||||||||||||
| Absent | 30 (75.0) | 12 (70.6) | 8 (42.1) | 0.729 | 0.014* | 0.086 | 9 (42.9) | 33 (34.1) | 38 (41.3) | 0.443 | 0.896 | 0.301 | |
| Present | 10 (25.0) | 5 (29.4) | 11 (57.9) | 12 (57.1) | 64 (65.9) | 54 (58.7) | |||||||
| PI | |||||||||||||
| Absent | 17 (42.5) | 4 (23.5) | 4 (21.1) | 0.290 | 0.188 | 0.823 | 7 (33.3) | 20 (20.6) | 27 (29.3) | 0.209 | 0.719 | 0.165 | |
| Present | 23 (57.5) | 13 (76.5) | 15 (78.9) | 14 (66.7) | 77 (79.4) | 65 (70.7) | |||||||
| pTumor depth | |||||||||||||
| pT1/2 | 17 (42.5) | 5 (29.4) | 8 (42.1) | 0.353 | 0.977 | 0.429 | 4 (19.1) | 18 (18.6) | 23 (25.0) | 0.797 | 0.769 | 0.283 | |
| pT3/4 | 23 (57.5) | 12 (70.6) | 11 (57.9) | 17 (80.9) | 79 (81.4) | 69 (75.0) | |||||||
| pLNM | |||||||||||||
| Absent | 23 (57.5) | 7 (41.2) | 7 (36.8) | 0.259 | 0.138 | 0.790 | 4 (19.1) | 15 (15.5) | 21 (22.8) | 0.938 | 0.932 | 0.270 | |
| Present | 17 (42.5) | 10 (58.8) | 12 (63.2) | 17 (80.9) | 82 (84.5) | 71 (77.2) | |||||||
| pTNM stage | |||||||||||||
| I/II | 26 (65.0) | 10 (41.2) | 10 (52.6) | 0.658 | 0.363 | 0.709 | 7 (33.3) | 30 (30.9) | 36 (39.1) | 0.829 | 0.622 | 0.237 | |
| III/IV | 14 (35.0) | 7 (58.8) | 9 (47.4) | 14 (66.7) | 67 (60.1) | 56 (60.9) | |||||||
EBV, Epstein-Barr virus; GC, gastric cancer; EBVaGC, EBV-associated GC; EBVnGC, EBV-negative GC; PD-L1, programmed death-ligand 1; STING, stimulator of interferon genes; LELC, lymphoepithelioma-like carcinoma; CLR, adenocarcinoma with Crohn’s disease-like lymphocytic reaction; CA, conventional adenocarcinoma; LVI, lymphatic vascular invasion; PI, perineural invasion; LNM, lymph node metastasis; NA, not available.
*Statistically significant, p<0.05; †STING & PD-L1+ vs STING or PD-L1+; ‡STING & PD-L1+ vs STING & PDL1–; §STING or PD-L1+ vs STING & PD-L1–.